Policy

Dr Sarfaraz K. Niazi Claims Biosimilar Growth Signals Need for Greater Testing, Policy Reform

April 28th 2022

By Skylar Jeremias

Now that the United States’ acceptance of biosimilars matches that in the European Union, developers should be encouraging changes to testing regulations to increase biosimilar accessibility, according to Sarfaraz K. Niazi, PhD, in his recent perspective paper.

Opinion: Biosimilar Adoption Will Help Achieve a Bipartisan Goal

April 25th 2022

By Robert Popovian, PharmD, MS

Article

Biosimilars provide significant savings and encourages competition in the biopharmaceutical marketplace but the United States needs to do more to empower uptake and address adoption barriers, according to Robert Popovian PharmD, MS.

Prioritizing Reference Products Over Biosimilars Led to Millions in Missed Savings for Part D

April 20th 2022

By Skylar Jeremias

Article

Medicare Part D plans missed out on between $84 million and $143 million in savings by not prioritizing the use of biosimilars over reference products, according to a report from the HHS Office of Inspector General.

Dr Edward Arrowsmith Discusses Clinical Pathways, Biosimilars in Ensuring Quality of Care

April 5th 2022

By Skylar Jeremias

Video

Edward Arrowsmith, MD, discussed his recent paper on the use of clinical pathways for specific cancer types and how biosimilar development can help ensure quality of care for patients with limited therapeutic options.

Americans Say Drug Costs Are Too High, and They Are Right

April 2nd 2022

By Juliana M. Reed

Article

The executive director of the Biosimilars Forum calls for policies to support adoption of lower-cost biologics.

Jeffery Casberg Previews His Presentations at AMCP 2022

March 27th 2022

By Skylar Jeremias

Video

Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products coming down the pipeline at the upcoming Academy of Managed Care Pharmacy (AMCP) annual meeting.

Blood Clot Prevention Biosimilars Achieve Reimbursement in British Columbia

March 24th 2022

By Skylar Jeremias

Podcast

Three biosimilars used for blood clot prevention secure public reimbursement status in British Columbia, one of several Canadian provinces that has a biosimilar switching program.

HHS, FDA Advances for Clinical Trials Will Boost Information on Biosimilars Use Among Senior Citizens

March 19th 2022

By Skylar Jeremias

Article

As HHS prepares to begin a study that will summarize the use and spending of biosimilars within Medicare Part B plans, the FDA updates its clinical trial guidance to expand enrollment access to senior patients.

Gillian Woollett Recaps the Festival of Biologics 2022

March 17th 2022

By Skylar Jeremias

Video

Gillian Woollett, MA, Dphil, vice president and head of regulatory strategy and policy at Samsung Bioepis, reviews some of the presentations, including her own, from the Festival of Biologics conference.

FDA Accepts BLAs Supporting Interchangeability From Alvotech, Pfizer for Biosimilars to Humira

February 28th 2022

By Skylar Jeremias

Article

The FDA has accepted biologics license applications (BLAs) for interchangeability status from Alvotech and Pfizer regarding their respective adalimumab biosimilars referencing Humira.